New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
08:08 EDTREGN, SNYSanofi and Regeneron report positive Phase 2 results of alirocumab
Sanofi (SNY) and Regeneron (REGN) announced that nine new Phase 3 Odyssey trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared to placebo or active comparator. In the nine trials, the mean percent reduction in LDL-C from baseline at 24 weeks in alirocumab-treated patients was consistent with results seen in previous alirocumab trials. A lower rate of adjudicated major cardiovascular events was observed in the alirocumab arm compared to placebo in a post-hoc analysis. The potential of alirocumab to demonstrate cardiovascular benefit is being prospectively assessed in an ongoing 18,000-patient Odyssey Outcomes trial. Alirocumab was generally well tolerated in the 9 trials.
News For SNY;REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
08:01 EDTREGNPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information
December 4, 2014
11:12 EDTSNYSanofi diabetes sales head left company, Bloomberg says
Subscribe for More Information
06:47 EDTREGNRegeneron removed from Top Picks List at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use